The American Society of Clinical Oncology’s annual meeting is online this year due to COVID-19, and Peter Mac will be on the virtual centre stage.
In a first, our Professor Linda Mileshkin will speak during the ASCO 2021 Plenary (starting 3am on Monday).
This is understood to be the first time anyone from Peter Mac has presented in the Plenary, and possibly the first time an Australian working in Australia has done so.
Professor Mileshkin will discuss the practice-changing outcomes of OUTBACK - a Phase III clinical trial which assessed chemotherapy plus standard treatment for women with locally advanced cervical cancer.
Also notably, Professor Geoff Lindeman will provide results from the VERONICA trial – a Phase II study involving venetoclax to treat locally advanced or metastatic breast cancer.
Professor Danny Rischin will provide an update on a novel biomarker in HPV associated oropharyngeal cancer, and a Phase III trial assessing radiotherapy plus chemotherapy in this cancer.
Professor John Seymour will discuss latest treatments in B-Cell Lymphomas while at this conference, data will be presented from Peter Mac involved studies of new treatments for chronic lymphocytic leukemia including a first head-to-head trial of acalbrutinib versus ibrutinib and a First-in-Human Study of the Novel BCL2 Inhibitor Lisaftoclax.
Peter Mac also has five invited faculty with Professor Grant McArthur, Professor John Seymour, Associate Professor Prue Francis, Associate Professor Jeanne Tie and Professor Danny Rischin all to lead education sessions, chair or be involved in panel discussions.
ASCO 2021 is underway from Friday until Tuesday, June 4-8. Review the program in full online.